Allarity Therapeutics, Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Japan Patent Office granted Japanese Patent No. 7917283 covering Allarity's stenoparib-specific Drug Response Predictor companion diagnostic, with protection extending to 2039. The patent covers DRP methods for predicting clinical benefit from stenoparib based on gene-expression profiles and patient selection. This complements existing U.S. patent protection (extending to April 2042) and European/Australian coverage, strengthening IP protection in a major pharmaceutical market.
Why this rating
Patent grant is operationally positive but modest in absolute terms. Early-stage biotech with $14.7M market cap; IP protection is necessary but not revenue-generating. Stenoparib still in Phase 2; clinical/regulatory risk remains high.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.